A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.

類似資料

• A gene signature for selecting benefit from hypoxia modification of radiotherapy for high risk bladder cancer patients
  著者:: Yang, L, 等
  出版事項: (2017)
• Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer
  著者:: Irlam-Jones, J, 等
  出版事項: (2016)
• Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial
  著者:: Eustace, A, 等
  出版事項: (2013)
• Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.
  著者:: Eustace, A, 等
  出版事項: (2013)
• Hypoxia regulated miRNAs in bladder cancer
  著者:: Blick, C, 等
  出版事項: (2012)